4.5 Review

Proton channels and exchangers in cancer

期刊

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
卷 1848, 期 10, 页码 2715-2726

出版社

ELSEVIER
DOI: 10.1016/j.bbamem.2014.10.015

关键词

Cancer; Carbonic anhydrases; Monocarboxylate transporters; Na+/H+ exchanger; Proton exchangers; V-ATPase

资金

  1. Italian Association for Cancer Research (I'AIRC) [11348]
  2. Italian Ministry of Health
  3. Mercedes Castresana Foundation, Vitoria, Spain
  4. Association for Proton Cancer Research and Treatment (APCRT), Madrid, Spain
  5. European Research Council [243188]
  6. Interuniversity Attraction Pole (IAP) grant from Belgian Science Policy Office (Belspo) [UP7-03]
  7. Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS)
  8. Fonds Joseph Maisin
  9. Communaute Francaise de Belgique (ARC) [09/14-020]
  10. Fondation Beige Contre le Cancer
  11. Belgian Federal Agency for Nuclear Control (AFCN-FANC)
  12. Association for International Cancer Research
  13. Swedish Cancer Society
  14. Worldwide Cancer Research [11-0522] Funding Source: researchfish
  15. European Research Council (ERC) [243188] Funding Source: European Research Council (ERC)

向作者/读者索取更多资源

Although cancer is characterized by an intratumoral genetic heterogeneity, a totally deranged pH control is a common feature of most cancer histotypes. Major determinants of aberrant pH gradient in cancer are proton exchangers and transporters, including V-ATPase, Na+/H+ exchanger (NHE), monocarboxylate transporters (MCTs) and carbonic anhydrases (CAs). Thanks to the activity of these proton transporters and exchangers, cancer becomes isolated and/or protected not only from the body reaction against the growing tumor, but also from the vast majority of drugs that when protonated into the acidic tumor microenvironment do not enter into cancer cells. Proton transporters and exchangers represent a key feature tumor cells use to survive in the very hostile microenvironmental conditions that they create and maintain. Detoxifying mechanisms may thus represent both a key survival option and a selection outcome for cells that behave as unicellular microorganisms rather than belonging to an organ, compartment or body. It is, in fact, typical of malignant tumors that, after a clinically measurable yet transient initial response to a therapy, resistant tumor clones emerge and proliferate, thus bursting a more malignant behavior and rapid tumor progression. This review critically presents the background of a novel and efficient approach that aims to fight cancer through blocking or inhibiting well characterized proton exchangers and transporters active in human cancer cells. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers. (C) 2014 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据